Title Body

Associate Professor, Pharmaceutical Sciences
Postdoctoral Studies, 2004, Cleveland Clinic Foundation
Ph.D. in Pharmacology, 2001, University of Kentucky
B.S. in Pharmacy, 1994, Butler University

Dr. McCune currently serves as an instructor in pharmacology and medicinal chemistry in the Pharmacotherapeutics course sequence as well as a specialized course, the Neuropharmacology of Drugs of Abuse.  In the laboratory, Dr. McCune in engaged in studies designed to characterize subtype specific differences in signal transduction and function of the alpha1-adrenergic receptors.  Dr. McCune also regularly acts as faculty escort for pharmacy students engaged in the study of medicinal plants of the Peruvian Amazon and is the coach of the Wilkes University Fencing Club.

Ajay Bommareddy, William Eggleston, Stacy Prelewicz, Andrea Antal, Zbigniew Witczak, Dan F. McCune and Adam L. VanWert, Chemoprevention of Prostate Cancer by Major Dietary Phytochemicals, Anticancer Research 33: 4163-4174 (2013).
García-Cazarín, M.L., Smith, J.L., Olszewski, K.A., McCune, D.F. ,Simmerman, L.A., Hadley, R.W., Kraner, S.D., Piascik, M.T.  The α1D-Adrenergic Receptor is Expressed Intracellularly and Coupled to Increases in Intracellular Calcium and Reactive Oxygen Species in Human Aortic Smooth Muscle Cells. Journal of Molecular Signaling. 2008, 3:6.
Shi T, Gaivin RJ, McCune DF, Gupta M, and Perez DM.  Dominance of the alpha1B-adrenergic receptor and its subcellular localization in human and TRAMP prostate cancer cell lines. J Recept Signal Transduct Res. 2007;27(1):27-45.
Papay R, Gaivin R, Jha A, McCune DF, McGrath JC, Rodrigo MC, Simpson PC, Doze VA, and Perez DM.  Localization of the mouse α1A-adrenergic receptor in the brain: α1A-AR is expressed in neurons, GABAergic interneurons and NG2 oligodendrocyte progenitors. J Comp Neurol. 2006 Jul 10;497(2):209-22.
Sohn JT, Ding X, McCune DF, Perez DM, Murray PA.  Fentanyl attenuates alpha1B-adrenoceptor-mediated pulmonary artery contraction.  Anesthesiology. 2005;  103:(2)327-34.
Rorabaugh BR, Ross SA, Gaivin RJ, Papay RS, McCune DF, Simpson PC, and Perez DM.   alpha1A- but not alpha1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrine-insensitive mechanism.  Cardiovasc Res. 2005;  65:(2)436-45.
McCune D, Gaivin R, Rorabaugh B, Perez D.  Bulk is a determinant of oxymetazoline affinity for the alpha1A-adrenergic receptor.  Receptors Channels. 2004;  10:(3-4)109-16. 
Papay R, Gaivin R, McCune DF, Rorabaugh BR, Macklin WB, McGrath JC, and Perez DM.   Mouse alpha1B-adrenergic receptor is expressed in neurons and NG2 oligodendrocytes.  J Comp Neurol. 2004;  478:(1)1-10. 
Gonzalez-Cabrera PJ, Shi T, Yun J, McCune DF, Rorabaugh BR, Perez DM.  Differential regulation of the cell cycle by alpha1-adrenergic receptor subtypes.  Endocrinology. 2004;  145:(11)5157-67.
Yun J, Gaivin RJ, McCune DF, Boongird A, Papay RS, Ying Z, Gonzalez-Cabrera PJ, Najm I, and Perez DM.   Gene expression profile of neurodegeneration induced by alpha1B-adrenergic receptor overactivity: NMDA/GABAA dysregulation and apoptosis.  Brain. 2003;  126:(Pt 12)2667-81. 
Ross SA, Rorabaugh BR, Chalothorn D, Yun J, Gonzalez-Cabrera PJ, McCune DF, Piascik MT, and Perez DM.   The alpha(1B)-adrenergic receptor decreases the inotropic response in the mouse Langendorff heart model.  Cardiovasc Res. 2003;  60:(3)598-607. 
Chalothorn D, McCune DF, Edelmann SE, Tobita K, Keller BB, Lasley RD, Perez DM, Tanoue A, Tsujimoto G, Post GR, and Piascik MT.  Differential cardiovascular regulatory activities of the alpha 1B- and alpha 1D-adrenoceptor subtypes.  J Pharmacol Exp Ther. 2003;  305:(3)1045-53. 
Gonzalez-Cabrera PJ, Gaivin RJ, Yun J, Ross SA, Papay RS, McCune DF, Rorabaugh BR, and Perez DM.  Genetic profiling of alpha 1-adrenergic receptor subtypes by oligonucleotide microarrays: coupling to interleukin-6 secretion but differences in STAT3 phosphorylation and gp-130.  Mol Pharmacol. 2003;  63:(5)1104-16. 
Yun J, Zuscik MJ, Gonzalez-Cabrera P, McCune DF, Ross SA, Gaivin R, Piascik MT, and Perez DM.  Gene expression profiling of alpha(1b)-adrenergic receptor-induced cardiac hypertrophy by oligonucleotide arrays.  Cardiovasc Res. 2003;  57:(2)443-55. 
Papay R, Zuscik MJ, Ross SA, Yun J, McCune DF, Gonzalez-Cabrera P, Gaivin R, Macklin WB, Drazba J, and Perez DM.   Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.  J Neurochem. 2002;  83:(3)623-34. 
Chalothorn D, McCune DF, Edelmann SE, Garcia-Cazarin ML, Tsujimoto G, Piascik MT.  Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes.  Mol Pharmacol. 2002;  61:(5)1008-16. 
McCune DF, Edelmann SE, Olges JR, Post GR, Waldrop BA, Waugh DJ, Waugh DJJ, Perez DM, and Piascik MT.   Regulation of the cellular localization and signaling properties of the alpha(1B)- and alpha(1D)-adrenoceptors by agonists and inverse agonists.  Mol Pharmacol. 2000;  57:(4)659-66.
Hrometz SL, Edelmann SE, McCune DF, Olges JR, Hadley RW, Perez DM, and Piascik MT.   Expression of multiple alpha1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction.  J Pharmacol Exp Ther. 1999;  290:(1)452-63. 

Alpha1-adrenergic receptors (α1-ARs) are proteins expressed throughout the cardiovascular system that play a role in the maintenance of systemic blood pressure, heart rate, the force of cardiac contractions, and the growth of vascular cells.  Three α1-adrenergic receptor (AR) subtypes have been characterized, the α1A-, α1B-, and α1D-AR. Evidence suggests functional effects of receptor activation is both subtype selective and tissue specific.  For example, the activation of the extracellular signal-regulated kinase (ERK) enzyme in cardiomyocytes appears to be α1A-AR dependent, and may be cardioprotective in heart failure.  This raises the possibility of utilizing α1A-AR selective agonists as adjunct therapy for patients with heart failure; however, much more information regarding α1-AR subtype selective effects (or potential side effects) in the vasculature is needed.  We examined subtype specific ERK activation in human primary arterial coronary smooth muscle cells, preliminary data suggesting ERK activation is blocked by α1D-AR selective antagonists and is not induced by α1A-AR selective agonists. If α1A-AR selective agents were used in heart failure, our data would suggest that ERK activation in peripheral vasculature would be minimal; therefore mitigating concern of α1A-AR mediated vascular injury as a result of therapy.  We propose to complete studies on ERK activation on smooth muscle cells from aortic, coronary, and pulmonary arterial tissues.

Preceptor, Study of Medicinal Plants of the Amazon (2010, 2013)
Teacher of the year (2010-2011)
Luxuriant Flowing Hair Club for Scientists (LFHCfS) (2007)
Founding member and executive committee member of the Northeastern Pennsylvania Division of the United States Fencing Association (2004 – current)
Founder and coach of the Wilkes University Fencing Club (2004 – current)
Individual National Research Service Award (NRSA) from the NIH (2002-2004)
Advanced Predoctoral Fellowship in Pharmacology/Toxicology for 2000-2001 from the Pharmaceutical Research and Manufacturers of America Foundation (PhRMA)
University of Kentucky Fellowship 1997-1998
Rho Chi Honor Society and Phi Eta Sigma Honor Society